{"entity":{"id":"vnx-202","kind":"drug","name":"VNX-202","aka":["AAV.CD3/HER2"],"tldr":"VNX-202 is an experimental in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics, in phase 1 trials for HER2-expressing solid tumours.","summary":"VNX-202 (AAV.CD3/HER2) is an in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics. A single intravenous dose of an adeno-associated virus vector encoding a CD3 x HER2 bispecific T-cell engager. Its furthest stage is phase 1, for HER2-expressing solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07192432 recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Vironexis Biotherapeutics: vironexis.com","url":"https://vironexis.com"},{"label":"Vironexis Biotherapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07192432"},{"label":"ClinicalTrials.gov: trials of VNX-202","url":"https://clinicaltrials.gov/search?intr=VNX-202"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["her2","cd3"],"drugs":[],"companies":["vironexis-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07192432"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"VNX-202","modality":"In vivo gene therapy: AAV vector encoding a bispecific T-cell engager","mechanism":"A single intravenous dose of an adeno-associated virus vector encoding a CD3 x HER2 bispecific T-cell engager.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vnx-202/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/"}],"trial":[{"id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","route":"/trials/nct07192432/"}]}}